Cardlytics Reports Q1 Revenue Decline Amid Strategic Shift, Achieves Positive Adjusted EBITDA and Boosts Liquidity

summarizeSummary

Cardlytics, Inc. reported a 39% year-over-year revenue decline for Q1 2026 but achieved positive Adjusted EBITDA and significantly improved its net loss and operating cash flow, driven by the divestiture of its Bridg platform and cost optimization.

check_boxKey Events

• Q1 2026 Financial Results

  Revenue decreased 39% year-over-year to $34.3 million, but net loss improved to $(4.5) million from $(13.3) million in Q1 2025.

• Positive Adjusted EBITDA

  Achieved positive Adjusted EBITDA of $0.23 million in Q1 2026, a notable improvement from a $(4.12) million loss in Q1 2025.

• Bridg Divestiture & Liquidity Boost

  Completed the sale of its Bridg platform, receiving 1,810,222 shares of PAR common stock, which were subsequently sold for $23.0 million in cash. $20.1 million of these proceeds were used to repay the 2018 Line of Credit.

• Operational Headwinds

  Monthly Qualified Users (MQUs) decreased by 8% and Adjusted Contribution per User (ACPU) by 23%, primarily due to a U.S. financial institution partner exiting the platform.

auto_awesomeAnalysis

This 10-Q provides a detailed look into Cardlytics' Q1 2026 performance, confirming the strategic shift initiated with the divestiture of the Bridg platform. While GAAP revenue saw a substantial 39% year-over-year decrease, the company successfully achieved positive Adjusted EBITDA of $0.23 million, a significant improvement from a $4.12 million loss in the prior year. Net loss also narrowed considerably. The sale of the Bridg platform generated $23.0 million in cash, which was used to repay $20.1 million of the company's line of credit, strengthening its balance sheet and liquidity. The reduction in the minimum unrestricted cash covenant further aids financial flexibility. However, the decline in Monthly Qualified Users (MQUs) and Adjusted Contribution per User (ACPU) due to a key FI partner exit highlights ongoing operational challenges in its core Cardlytics platform. Investors should monitor the company's ability to stabilize its user base and revenue growth in continuing operations while maintaining profitability.